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Introduction 
 
In recent years, galectins (Gal), a protein family with ß
-galactoside binding affinity, have gained increasing 
attention as important drivers of many different dis-
eases including cancer (Ebrahim et al. 2014). Carbohy-
drate binding is mediated through a conserved carbo-
hydrate recognition domain (CRD) and major ligands 
are branched N-glycans found on transmembrane pro-
teins promoting the formation of galectin lattices 
modulating signaling cascades (Wu et al. 2011). By 
translating the sugar code into molecular functions 
galectins can therefore affect processes such as cell-
cycle progression, differentiation, apoptosis, cell-cell 
interaction and adhesion to the extracellular matrix 
(Gabius et al. 2016, Kaltner et al. 2017). In addition, in 
particular for intracellular functions, also direct glycan
-independent galectin-protein interactions have been 
suggested (Liu & Wang 2002, Wang et al. 2004). 
Thus, maintaining cellular homeostasis requires tight-
controlled gene expression levels by various mecha-
nisms and abnormal expression has been linked to tu-
mor initiation and progression including colon cancer 
(CRC) (Thijssen et al. 2015, Timoshenko 2015, Wu et 
al. 2013).  
 CRC carcinogenesis is associated with an in-
crease in Gal-1, -3 and -7 expression and decrease of 
Gal-2, -4, -8, -9 and -12 levels thereby contributing to 
key processes like metastasis formation and immune 
evasion (Barrow et al. 2011, Gopalan et al. 2016, Kim 
et al. 2013, Thijssen et al. 2015). For instance, Gal-3 
binds to oncofetal Thomsen-Friedenreich antigen on 
the transmembrane protein MUC1 promoting its cell 
surface polarization resulting in enhanced adhesion of 
cancer cells to the vascular endothelium (Mori et al. 
2015). On the contrary, Gal-4 exerts a tumor suppres-
sive function by induction of cell cycle arrest and dif-
ferentiation (Michalak et al. 2016, Satelli et al. 2011). 
Compared to Gal-1 and -3 which are the most exten-
sively studied members of this family, the functional 
role of Gal-12 has only rarely been investigated. Gal-
12, encoded by the LGALS12 gene, is a bivalent tan-
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Several members of the glycan-binding family of 
galectins have been linked to colon cancer initiation 
and progression while the role of galectin-12 in this 
malignancy is largely unexplored. In previous studies 
we observed expression of galectin-12 in normal colon 
epithelium in contrast to its lack of expression in colo-
rectal cancer tissues. In order to gain insight into its 
molecular function we established a genetically engi-
neered colon cancer model cell line, which facilitates 
inducible and reconstituted expression of LGALS12 
transgene at physiological levels in an isogenic back-
ground. Regulation of transgene expression by doxy-
cycline was confirmed at the transcript- and protein 
level in a time- and dose-dependent manner for two 
independent clones. Reconstituted galectin-12 expres-
sion did not affect cell morphology and proliferation. 
Analysis of its subcellular distribution showed that 
galectin-12 resides in and shuttles between the nucleus 
and cytoplasm. More detailed analysis by double-
immunofluorescence and confocal microscopy re-
vealed colocalization of galectin-12 with splicing-
factor rich nuclear speckles, hinting towards a potential 
role of galectin-12 in pre-mRNA splicing and process-
ing. Therefore, the established model cell line repre-
sents a powerful tool to investigate the functional im-
pact of galectin-12 reconstitution on colon cancer tu-
morigenesis. 
Abstract 
dem-repeat type galectin, which consists of 2 CRDs 
joined by a short linker sequence. Lactose binding af-
finity has been confirmed, though the C-terminal CRD 
lacks several of the key amino acid residues known to 
be responsible for carbohydrate interaction and are 
conserved among the other members of the family 
(Yang et al. 2001). Most tissues and cell lines are char-
acterized by low mRNA levels of LGALS12, however 
strong expression has been observed in peripheral 
blood and myeloid cells as well as adipocytes (Yang et 
al. 2001). Gal-12 expression can also be triggered by 
different conditions such as oxidative stress and differ-
entiation (Vinnai et al. 2017, Yang et al. 2004). The 
vacuolar protein VPS13C has been identified as an 
interacting partner of Gal-12 and loss of VPS13C ex-
pression results in rapid degradation of Gal-12 through 
the lysosomal pathway (Yang et al. 2016). While the 
biological role of Gal-12 has been mainly studied in 
adipocytes, the function in other cell types is largely 
unexplored. In adipocytes abrogation of Gal-12 se-
verely impairs cellular differentiation and adipogenic 
signaling by downregulation of critical transcription 
factors such as CCAAT/enhancer-binding protein 
(Yang et al. 2004). Ablation of Gal-12 in mice in-
creases mitochondrial respiration, reduces inflamma-
tion and adiposity suggesting involvement in meta-
bolic disorders (Yang et al. 2011).There is also grow-
ing evidence that Gal-12 could be an important modu-
lator in controlling tumor growth and progression. Ec-
topic expression can affect proliferation and possesses 
apoptosis-inducing activity in tumor cells of different 
origin (Hotta et al. 2001, Yang et al.2001). Further-
more, downregulation of LGALS12 mRNA has been 
observed in several tumor entities and correlates with 
lower overall survival as well as enhanced prevalence 
of tumor recurrence and lymphovascular invasion (El 
Leithy et al. 2015, Gopalan et al. 2016, Laderach et al. 
2013, Salajegheh et al. 2014).  
 We have previously reported that loss of Gal-
12 expression is associated with promotor hyper-
methylation in CRC cells and de novo expression can 
be triggered upon induction of differentiation by bu-
tyrate, a short chain fatty acid involved in maintaining 
intestinal homeostasis (Katzenmaier et al. 2017, 
Katzenmaier et al. 2014). In accordance with the data 
obtained from our in vitro study Gal-12 was found to 
be constitutively expressed in the differentiated 
healthy colon epithelium but significantly decreased in 
corresponding tumor tissue (Katzenmaier et al. 2017). 
Galectins are known as important modulators of cell 
growth and differentiation. However, the extent to 
which silencing of Gal-12 contributes to growth ad-
vantages of colon tumor cells and its biological func-
tion in CRC remains still unclear. In the present study 
we therefore established a doxycycline-inducible Gal-
12 expressing CRC cell line, which enables to study 
the impact of Gal-12 reconstitution on CRC tumori-
genesis. Time- and dose-dependent Gal-12 expression 
as well as the intracellular distribution pattern were 
examined. In addition, we demonstrate for the first 
time colocalization of Gal-12 with splicing speckles in 
the nucleus, suggesting involvement in pre-mRNA 
splicing and processing. 
 
Materials and Methods 
 
Plasmids 
The retroviral expression plasmid S2F-cLM2CG-
FRT3 contains a tet-controlled bidirectional transcrip-
tion unit, which facilitates Doxycycline (Dox)-
dependent expression of the two reporter genes firefly 
luciferase and red fluorescent protein mCherry 
(Weidenfeld et al. 2009). Additionally, the expression 
cassette is flanked by two recombination sites, a mu-
tated F3 and wildtype F site, that can be recognized by 
Flpo-recombinase (Schlake & Bode 1994). For genera-
tion of the S2F-cLM2CG-FRT3-Gal12 construct the 
EcoR 1/Not 1 mCherry fragment was replaced by hu-
man galectin-12 (Gal-12) full-length cDNA 
(NM_033101) derived from SW707 cells, cultured in 
the presence of 1 mM NaBut for 7 days, resulting in de 
novo expression of LGALS12 at transcript level. cDNA 
was amplified using primers carrying EcoR 1 and Not 
1 restriction sites as well as a N-terminal Flag-Tag se-
quence. Verification of the amplified LGALS12 se-
quence, with or without integrated Flag-Tag, was con-
firmed by sequencing. The plasmid pCAGGS-Flpo-
IRES-Puro encodes for Flpo-recombinase, which was 
used for recombinase mediated cassette exchange 
(RMCE). 
 
Cell Lines and Culture Conditions 
Cell lines were either cultured in DMEM-F12 (PAA, 
Cölbe, Germany) (HCT116-Tet-On, HCT116-HygTK, 
HCT116-Gal12) or RPMI1640 (PAA, SW707 cell 
line) supplemented with 10% FBS (PAA), 1% Penicil-
lin (PAA) and 1% Streptomycin (PAA) at 37 °C in a 
humidified atmosphere containing 5 % CO2. HCT116-
Tet-On cells are stably transfected with a construct 
facilitating constitutive expression of a reverse transac-
tivator (rTA) and EGFP. (Welmann et al. 2006). 
HCT116-HygTK cells additionally contain a hygromy-
cin B thymidine kinase (HygTK) expression cassette 
flanked by two recombination sites (F/F3) conferring 
hygromycin resistance (Lee et al. 2013). Cells were 
regularly checked for mycoplasm contamination using 
the Mycoplasma Detection Kit from Minerva Biolabs 
(Berlin, Germany). For reconstitution of Gal-12 ex-
29   Journal of Molecular Biochemistry, 2018 
pression, cells were either grown in the presence or 
absence of 1 µg/ml Dox (Sigma-Aldrich, Taufkirchen, 
Germany) for 48 h. To investigate time- and dose-
dependent inducible expression of LGALS12, cells 
were grown in the presence or absence of 1 µg/ml Dox 
for 30 min up to 96 h and incubated with different con-
centrations of Dox (0.005-1 µg/ml) for 48 h respec-
tively.  
 
Generation of HCT116-Gal12 Cells 
HCT116-Gal12 cells were generated by using the mas-
ter cell line HCT116-HygTK, which is hygromycin 
resistant but sensitive to ganciclovir. 107 cells were 
electroporated with 3 µg of S2F-cLM2CG-FRT3-
Gal12 and 1 µg of pCAGGS-Flpo-IRES-Puro plasmid 
using the AmaxaCell Line Nucleofactor Kit V (Lonza, 
Basel, Switzerland) according to the manufactures in-
structions. Upon RMCE the integrated HygTK expres-
sion cassette was replaced by an expression cassette 
encoding for luciferase and Gal-12. After 24 h 1.5 µg/
ml puromycin (Sigma-Aldrich) was added to the 
growth medium for 36 h followed by selection with 
40 µM Ganciclovir (Roche, Mannheim, Germany) for 
at least 2 weeks. Integration of the expression cassette 
in individual clones was confirmed by sequencing and 
the inducibility was determined by performing quanti-
tative real-time PCR and western blot analysis as well 
as measuring luciferase activity  
 
Reverse Transcriptase PCR (RT-PCR) and Quanti-
tative Real-Time PCR (qRT-PCR) 
Total RNA was extracted employing RNeasy Mini Kit 
(Quiagen, Hilden, Germany) following the manual 
procedure. 1 µg of total RNA was subsequently tran-
scribed into cDNA as described previously 
(Katzenmaier et al. 2014). Human full-length 
LGALS12 cDNA of SW707 cells was amplified with 
primer carrying an EcoR 1 and Not 1 restriction site as 
well as a Flag-Tag sequence under following cycle 
conditions: activation of DNA polymerase (Phusion 
High Fidelity DNA Polymerase; Biocat GmbH, Hei-
delberg; Germany) at 98 °C for 30 sec followed by 40 
cycles at 98 °C for 10 sec and 72 °C for 40 sec with a 
final extension at 72 °C for 10 min. For qRT-PCR 
analysis cDNA was diluted 1:10 and analyzed in tripli-
cates using the StepOne Plus thermo cycler (Applied 
Biosystems, Thermo Fisher Scientific, Waltham, 
USA). The cycling program was as followed: 95 °C 
for 10 min, followed by 40 cycles at 95 °C for 15 sec 
and 60 °C for 1 min. Gene expression was normalized 
to expression of the housekeeping gene Hydroxy-
methylbilan-Synthase (HMBS). Data quantification 
was performed by applying StepOne Software v2.1. 
Fold change of expression was determined according 
to the ΔΔCt method (Livak & Schmittgen 2001). 
Primer sequences are given in Table S1. 
 
DNA Sequence Analysis 
Genomic DNA of HCT116-Gal12 cells was extracted 
using DNeasy Blood and Tissue Kit (Quiagen) follow-
ing the manufacturer’s instructions. Sequencing of the 
amplified gDNA and cDNA of LGALS12 was per-
formed with the Big Dye Terminator v1.1 sequencing 
kit (Thermo Fisher Scientific) on an ABI3100 genetic 
analyzer. Sequencing primers are indicated in Table 
S1. 
 
Luciferase Assay 
Luciferase activity was determined in duplicates by the 
Luciferase Assay System (Promega Mannheim, Ger-
many) according to the manufacturer’s protocol. Rela-
tive light units were normalized to protein concentra-
tion measured by Bradford assay (Bio Rad, Munich, 
Germany). 
 
Western Blot Analysis 
Cells were lysed in RIPA buffer (50 mM Tris-HCl, 
150 mM NaCl, 0.1 mM CaCl2, 0.01 mM MgCl2, 1% 
Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 
pH 7.4) supplemented with protease inhibitors 
(cOmplete mini, Roche, Basel, Switzerland) and soni-
cated for 30 sec on ice. After incubation on a rotator at 
4 °C for 1 h, samples were centrifuged at 21.000 g and 
4 °C for 20 min. Subsequently, the supernatant was 
collected for western blot analysis and protein concen-
tration was determined by Bradford assay. Separation 
and blotting of proteins on a nitrocellulose membrane 
was carried out as previously described (Katzenmaier 
et al. 2014). Briefly, after blocking the membrane for 
at least 30 min at room temperature (RT) in 5% skim 
milk/TBST (20 mM Tris-HCl pH 7.5, 0.5 M NaCl and 
0.1% Tween-20) or 5% BSA/TBST, the following pri-
mary antibodies were used in blocking solution: rabbit 
anti-Flag (F7425, 1:500, 5% milk/TBST, overnight 4 °
C, Sigma-Aldrich), mouse anti-β-Actin (clone C4, 
1:2.000, 5% milk/TBST, overnight 4°C, MP Biomedi-
cals, Solon, USA), mouse anti -GAPDH 
(mAbcam9484, 1:1.000, 5% BSA/TBST, 1 h RT, Ab-
cam, Cambridge, GB) and rabbit anti-Lamin B1 (clone 
D9V6H, 1:1.000, 5% milk/TBST, overnight 4 °C, Cell 
Signaling Technology, Danvers, USA). After the incu-
bation period membranes were washed thrice with 
TBST (10 min each at RT) and incubated either with 
HRP-labeled anti-rabbit antibody (1:2.000, 5% milk/
TBST, Promega) or anti-mouse-IgG antibody (1:5.000, 
5% milk/TBST, GE Healthcare, Munich, Germany) for 
1 h at RT. Visualization of the proteins was performed 
by chemiluminescence. 
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Density gradient centrifugation 
2.4x106 HCT116-Gal12 cells were grown on T175 
flasks in the presence or absence of 1 µg/ml Dox for 
48 h. Subsequently, medium was removed and the cell 
layer was washed twice with ice cold PBS, scraped 
and centrifuged for 3 min at 800 g and 4 °C. Cell pel-
lets of 2 flasks were collected, resuspended in 1 ml cell 
lysis buffer (10 mM Tris-HCl, 10 mM NaCl, 3 mM 
MgCl2, 0.5% Nonidet P-40, pH 7.4) and applied on top 
of 3 ml sucrose buffer (0,7 M Sucrose, 60 mM KCl, 
15 mM NaCl, 15 mM Tris-HCl, 2 mM EDTA, 0.5 mM 
EGTA, 14  mM β-Mercaptoethanol, 0.1% Triton-X-
100, pH 7.5). In addition, trypan blue staining was per-
formed to control for cell lysis. After centrifugation for 
10 min at 1.300 g and 4 °C the cytoplasmic fraction 
was harvested from the top of the sucrose buffer and 
the nuclei, forming a cell pellet at the bottom of the 
tube, were resuspended in 500 µl RIPA cell lysis 
buffer supplemented with protease inhibitors. Protein 
concentration was determined by Bradford assay. 
 
Immunofluorescence staining and Imaging 
104 cells were grown on cover slips in the presence or 
absence of 1 µg/ml Dox for 48 h. Afterwards cells 
were washed once with PBS and fixed with ice cold 
acetone and methanol (8 min each, -20°C). Subse-
quently, cells were washed twice with PBS for 5 min, 
blocked with 10% BSA/PBS for 30 min (RT) and in-
cubated with the following primary antibodies in 
3% BSA/PBS in a humid chamber at 4 °C overnight: 
rabbit anti-DYKDDDDK Tag (clone D6W5B, 1:50, 
Cell Signaling) and mouse anti-SC35 (ab11826, 1:400, 
Abcam). Samples were washed thrice with PBS for 
5 min and incubated with the listed secondary antibod-
ies in 3% BSA/PBS for 1 h at RT: Alexa Fluor 488 
labeled anti-mouse IgG (A21121, 1:800, Thermo 
Fisher Scientific) and Alexa Fluor 594 labeled anti-
rabbit IgG (ThA21442, 1:200, Thermo Fisher Scien-
tific). After 3 washing steps with PBS (5 min each) 
counterstaining of the nuclei with DAPI (Thermo 
Fischer Scientific) was carried out in 3% BSA/PBS for 
10 min. Finally, cells were washed twice with PBS 
(5 min each) and embedded using DAKO Fluores-
cence Mounting Medium (DAKO, Hamburg, Ger-
many). For colocalization studies both primary as well 
as secondary antibodies were applied at the same time. 
Immunofluorescence analysis was carried out using an 
Olympus AX 70 (40 x magnification) microscope. For 
colocalization studies confocal laser scanning micros-
copy was conducted equipped with a Plan-Apochromat 
63x/1.40 Oil DIC objective, a UV diode 405 nm 
(DAPI), an Argon 488 nm (FITC) and Helium-Neon 
594 nm (TRITC) laser as well as reflected light pho-
tomultiplier tubes. Image acquisition and processing 
was performed using Leica LAS AF and ImageJ soft-
ware (Schindelin et al. 2012). Background was sub-
stracted with constant settings using ImageJ's Rolling 
ball background subtraction.  
 
MTT Assay 
Cells were grown on 96 well plates in the presence or 
absence of 1µg/ml Dox for up to 96 h. Proliferation 
was assessed by reduction of 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium to Formazan using the CellTiter 96® 
Aqueous One Solution Cell Proliferation Assay 
(Promega, Mannheim, Germany) according to the 
manufacturer`s protocol. 
 
Enzyme activity for Alkaline Phosphatase 
As a marker of cellular differentiation alkaline phos-
phatase activity was assessed in HCT116-Gal12 #5+F 
cells treated with or without 1µg/ml Dox for 5 days as 
described previously (Katzenmaier et al. 2014). One 
unit was defined as the amount of enzyme that hydro-
lyzes 1 µmol p-nitrophenylphosphate into p-
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Figure 1. Generation of HCT116-Gal12 cells by recombinase-mediated cassette exchange (RMCE). The master cell line 
HCT116-HygTK was used for RMCE (Lee et al. 2013). This cell line carries an expression cassette encoding for the fusion 
protein hygromycin B and thymidine kinase flanked by 2 Flpo-recombinase recognition sites, a wildtype (F) and mutant one 
(F3). These recombination sites facilitating the exchange of the expression cassette with a luciferase-Gal12 expression cassette 
by RMCE resulting in the model cell line HCT116-Gal12 (adapted from Lee et al.2013). 
Two independent clones of this master cell line have 
been established in our lab previously, differing in the 
integration site of the expression cassette, which is ei-
ther localized on chromosome 1 (C1orf159) for clone 
#5 and on chromosome 5 (ALDH1L1 gene, silenced by 
methylation in HCT116 cells (Lee et al. 2013, Oleinik 
& Krupenko 2011)) for clone #22. The luciferase-
Gal12 expression cassette was inserted directly at these 
defined loci by recombinase mediated cassette ex-
change resulting in HCT116-Gal12 #5 and #22 cells 
(Figure 1). In addition, and due to the lack of Gal-12 
specific antibodies, clones with an integrated Flag-tag 
at the N-terminus of Gal-12 were also generated (+F = 
with Flag, -F=without Flag). The established cell line 
therefore facilitates for the first time the investigation 
of the biological relevance of Gal-12 on CRC tumori-
genesis. 
 
Characterization of HCT116-Gal12 cells 
Next, two independent clones of our established model 
cell line were characterized in more detail. Dox treat-
ment with 1 µg/ml over 48 h resulted in an increase in 
luciferase activity (#5-F: 78x; #22-F: 345x) (Figure 
2A) as well as strong induction of the LGALS12 tran-
script by qRT-PCR (#5-F: 154, #22-F: 110x) (Figure 
2B) confirming the inducibility of the construct.  
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Figure 2. Induction of luciferase activity and LGALS12 mRNA expression by treatment with Doxycycline. HCT116-Gal12 #5-
F and #22-F cells were cultured in the presence or absence of 1 µg/ml Dox for 48 h. Treatment resulted in strong increase of 
luciferase activity (A) as well as induction of LGALS12 mRNA expression (B, qRT-PCR) in 2 independent clones, which dif-
fer in the integration site of the expression cassette. Values represent the mean of three independent experiments ± SD. Data 
are shown for clone HCT116-Gal12 #5-F and #22-F but also apply to clones expressing the Flag-tagged counterpart (not 
shown). 
nitrophenolate per minute. Protein concentration was 
determined by the method of Lowry. 
 
Results 
 
Generation of a Colorectal Cancer (CRC) Model 
Cell Line with Doxycyline-inducible Gal-12 Expres-
sion  
In order to investigate the functional consequence of 
Gal-12 expression on CRC tumorigenesis we estab-
lished a Gal-12 inducible CRC model cell line, which 
is a derivate of the CRC cell line HCT116. HCT116 
cells represent a suitable model to assess the functional 
role of Gal-12 because they lack expression of the 
LGALS12 gene similar to what has been observed in 
primary CRC tumors. Since Gal-12 has been reported 
to confer anti-proliferative and pro-apoptotic functions 
in different cell types a doxycycline-inducible (Tet-on) 
gene expression system was chosen to account for po-
tential growth suppressive functions in colorectal can-
cer cells (Wan et al. 2018). For generation of HCT116-
Gal12 cells the master cell line HCT116-HygTK was 
used, which constitutively expresses a dox-regulated 
reverse transactivator (rTA) and additionally contains 
an expression cassette flanked by 2 Flpo-recombinase 
recognition sites conferring hygromycin resistance. 
 Apart from the induction of the luciferase 
marker protein we also examined the Dox-inducible 
expression of the Gal-12 protein by western blot analy-
sis. Due to the lack of Gal-12 specific antibodies, two 
independent clones expressing N-terminal Flag-tagged 
Gal-12 fusion protein were used for these experiments 
(HCT116-Gal12 #5+F; HCT116-Gal12 #22+F). Dose-
dependent expression analysis revealed the highest 
induction of Gal-12 protein upon treatment with 1 µg/
ml Dox (Figure 3A). When we performed a time-
course analysis, Gal-12 expression was detectable al-
ready after 2 h and protein levels reached a peak within 
48 h (Figure 3B). Even after 96 h, a high level of Gal-
12 protein was observed which facilitates the investi-
gation of short and long-term effects of Gal-12 on 
CRC carcinogenesis. Remarkably, no Gal-12 protein 
was detectable in cells cultured without Dox confirm-
ing the lack of leakiness of the applied Tet-system. 
Since treatment with 1 µg/ml Dox for 48 h resulted in 
the strongest induction (Figure 3A) this concentration 
was chosen as a standard culture condition for all sub-
sequent experiments.  
 Inconsistent with the published literature (Wan 
et al. 2018) reactivation of Gal-12 expression did not 
induce any alterations in cell cycle progression or dif-
ferentiation status (Figure S3 A,B) of the model cell 
line. Also, no major differences were observed be-
tween both clones. Based on these results, our geneti-
cally engineered HCT116-Gal12 cells provide a useful 
model system to examine the cellular and molecular 
function of Gal-12 in more detail.  
 
 
Cell cycle-dependent subcellular distribution of Gal
-12 
Subcellular location of proteins can provide important 
clues about their potential cellular functions. Several 
studies have shown that galectins can be found in 
many distinct subcellular compartments as well as on 
the cell surface and in the extracellular milieu (Santos 
et al. 2016, Takenaka et al. 2004). However, the sub-
cellular localization of Gal-12 in CRC cells has not 
been explored yet. Therefore, we examined the subcel-
lular distribution profile of Gal-12 in HCT116-Gal12 
#5+F cells by cell fractionation and density gradient 
centrifugation. The purity of the separated fractions 
was verified by antibodies directed against well-
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Figure 3. Dose- and time-dependent induction of Gal-12 
protein expression. HCT116-Gal12 #5+F cells were cul-
tured either in the presence or absence of 0.1-1 µg/ml Dox 
for 48 h (A, dose-response) or 1 µg/ml Dox for up to 96 h 
(B, time-course) before Western blot analysis was per-
formed. The strongest induction of Gal-12 expression was 
achieved with 1 µg/ml Dox over 48 h. In the absence of 
Dox no Gal-12 protein was detectable. Data are shown for 
clone HCT116-Gal12 #5+F but also apply to clone HCT116
-Gal12 #22+F (not shown). 
Figure 4. Subcellular distribution of Gal-12. A) Subcellular 
fractions of HCT116-Gal12 #5+F cells, cultured for 48 h in 
the presence (+) or absence of (-) of 1 µg/ml Dox, were 
obtained by density gradient centrifugation. The purity of 
each fraction was confirmed by detection of nuclear Lamin 
B1 and cytoplasmic GAPDH protein using western blot 
analysis. Gal-12 was present in both fractions of Dox-
treated cells but was absent in untreated cells. HCT116-
Gal12 cells, previously documented to be positive for Gal-
12, served as a positive control (N =nuclear, C = cytoplas-
mic, W= whole cell lysate, PC= positive control) B). For 
immunofluorescence staining cells were grown on cover-
slips under the same culture conditions as described above. 
After 48 h cells were fixed and the nuclei were counter-
stained with DAPI (blue). Immunostaining of Gal-12 was 
performed as described in detail in Material and Methods 
using a Flag-antibody and an Alexa Fluor 594 labeled sec-
ondary antibody. Subcellular localization of Gal-12 (pink to 
red), indicated by white arrows, is shown for cells in the 
interphase and various stages of mitosis. Cells cultured in 
the absence of Dox served as a negative control (400x mag-
nification). 
A 
B 
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Figure 5. Colocalization analysis of Gal-12 with SC-35. Double immunofluorescence staining was performed to investigate 
colocalization of Gal-12 (Alexa Fluor 598) and SC-35 (Alexa Fluor 488) by confocal laser scanning microscopy (A). Cell nu-
clei were counterstained with DAPI. Gal-12 protein is shown in red whereas SC-35 is marked with green fluorescence. Overlay 
of the fluorescence signals confirms colocalization of both proteins (yellow and orange) in nuclear speckles of HCT116-Gal12 
#5+F cells cultured in the presence of 1 µg/ml Dox for 48 h. Corresponding scatter plots of untreated (B) and treated cells (C) 
represent the colocalization tendency between both proteins. The extent of colocalization was further assessed by calculation of 
Pearson`s correlation coefficients (R). Values reflect the mean of three analyzed cells in one visual field (D) from each culture 
condition ± SD (p < 0.001, t-test). Images and scatter plots of the additionally analyzed cells are shown in Supplementary Ma-
terial Fig. S1 and S2. 
A 
B 
C 
D 
established marker proteins of the nucleus (Lamin B1) 
and cytosol (GAPDH). As expected, Lamin B1 protein 
was enriched in the nuclear fraction whereas the glyco-
lytic enzyme GAPDH was found to be present in the 
cytoplasmic fraction only (Figure 4A). Interestingly, in 
Dox-treated HCT116-Gal12 #5+F cells, Gal-12 oc-
curred in both subcellular protein fractions but re-
mained undetectable in untreated cells. To investigate 
the spatio-temporal subcellular distribution pattern of 
Gal-12 more in detail immunofluorescence staining 
was performed using a Flag-specific antibody. Com-
pared to the results obtained by density gradient cen-
trifugation, Gal-12 was found to reside predominantly 
in the nucleus recognized as a speckled staining pattern 
sparing the nucleoli (Figure 4B). A more detailed 
analysis of the immunofluorescence images revealed 
that the subcellular distribution of Gal-12 seemed to 
vary in a cell cycle-dependent manner. Thus, looking 
at single Dox-treated cells at various stages of mitosis, 
the speckled staining pattern disappeared and Gal-12 
was found to be translocated to and homogeneously 
distributed in the cytoplasm without any nuclear stain-
ing (Figure 4B). Only a weak background fluorescence 
signal was visible in untreated HCT116-Gal12 #5+F 
cells confirming the specificity of the applied anti-
body. These results indicate, that the subcellular local-
ization of Gal-12 protein can vary significantly, and is 
potentially affected in a cell cycle-dependent manner. 
 
Gal-12 colocalizes to splicing-factor rich nuclear 
speckles 
The observed speckle-like distribution pattern of Gal-
12 in the nucleoplasm, sparing the nucleoli, is strik-
ingly reminiscent of that described for splicing-factor 
rich nuclear speckles, a subcellular compartment 
where splicing factors are stored or reassembled. Thus, 
in the next step colocalization of Gal-12 with serine/
arginine-rich splicing factor 2 (SC-35), a commonly 
used marker for nuclear speckles, was assessed by ap-
plying confocal laser scanning microscopy. Double 
immunofluorescence staining of SC-35 and Gal-12 
revealed strong colocalization of both proteins in the 
nuclei of Dox treated HCT116-Gal12 #5+F cells, rep-
resented by the yellow and orange color in the overlay 
of both images (Figure 5A, S1 C,D). The degree of 
colocalization was confirmed by analyzing the spatial 
correlation of the fluorescence signals obtained for 
each protein as indicated by quantitative scatter plots 
(Figure 5 B,C). Scatter plots of additionally analyzed 
cells are depicted in Supplementary Materials (Figure 
S2 A-D). The observed average Pearson correlation 
coefficient of 0.7 of 3 analyzed cells in one visual field 
indicates an overlap of both fluorescence signals of 
approximately 70 % (Figure 5D). The spatial distribu-
tion and expression of SC-35 remained unaffected by 
Dox treatment (Figure 5A, S1 A,B). Furthermore, only 
a weak background fluorescence signal intensity was 
obtained in untreated cells after incubation with flag-
specific antibody, confirming the specificity of the ob-
served staining pattern (Figure 5A, S1 A,B). These 
data for the first time demonstrate colocalization of 
Gal-12 with nuclear speckles, suggesting involvement 
in pre-mRNA splicing and processing, thereby point-
ing to a new functional role of this rarely studied mem-
ber of the galectin family.  
 
Discussion 
 
As translators of the sugar code, galectins have 
emerged as important modulators of tumor develop-
ment, progression and metastasis (André et al. 2015). 
Their biological function and mode of reprogramming 
during tumorigenesis has been well established for 
several members of this protein family (Dings et al. 
2018). Still, for some of them like Gal-12, their func-
tion in human malignancies, especially in colorectal 
carcinogenesis, has only rarely been investigated. In 
the present study we have established a CRC model 
cell line genetically engineered to enable inducible and 
reconstituted expression of a LGALS12 transgene. This 
model system has several major advantages. First and 
most importantly, this model cell line carries a single 
copy of the LGALS12 transgene integrated at a defined 
genomic locus in an isogenic background. Second, the 
use of independent clones differing in the genomic 
integration site of the LGALS12 transgene expression 
cassette enables to exclude any locus and clone-
specific effects. Third, transgene expression can be 
regulated by doxycycline in a dose-dependent and 
fully reversible manner, thereby enabling physiologi-
cal Gal-12 expression levels, and allowing the investi-
gation of short and long-term Gal-12-mediated effects 
on CRC tumorigenesis. Fourth, this model system can 
be applied to multi-omics approaches such as tran-
scriptome, proteome and secretome analysis and can 
also be used in xenograft studies thereby facilitating 
detailed functional analysis at the molecular level. Fi-
nally, this inducible expression system represents a 
versatile tool that can be easily adapted to any other 
galectin or gene of interest. When using this model cell 
line it should, however, be recalled that this reconsti-
tuted Gal-12-expression system reflects the inverse 
situation of primary CRC tumors which are character-
ized by loss of LGALS12 expression (Katzenmaier et 
al. 2017).  
 When we examined the molecular and cellular 
consequences of reconstituted LGALS12 transgene ex-
pression in this model system, none of the two inde-
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pendent clones showed any alterations of cell size, 
shape or morphology under optimal induction condi-
tions. Likewise, reconstituted expression of Gal-12 did 
not affect cell growth and differentiation of these cul-
tured cells. In our previous study Gal-12 was found to 
be de novo expressed upon induction of differentiation 
of CRC cells (Katzenmaier et al. 2014). Studies in 
HeLa cells and adipocytes revealed that ectopic ex-
pression of Gal-12 leads to growth arrest and differen-
tiation (Yang et al. 2001, 2004). Several explanations 
might account for these apparently opposing results. 
First, Gal-12 might not primarily drive differentiation 
of CRC cells but rather is involved in maintaining cel-
lular homeostasis of cells with a higher degree of dif-
ferentiation. Second, appropriate i.e. just right levels of 
Gal-12 expression might be required for specific bio-
logical functions. Compared to the literature using cell 
lines with multiple integration sites of the LGALS12 
transgene our model system carries just one copy re-
flecting more likely physiological levels of Gal-12 pro-
tein (Yang et al. 2001). Such dose-dependent effects 
have been already reported for Gal-1 causing biphasic 
modulations of cell growth (Adams et al. 1996). Fur-
thermore, alternative splicing gives rise to multiple 
isoforms of LGALS12 differing in the length of the 
linker connecting both CRDs. Since tissue dependent 
effects of Gal-12 on cellular differentiation have been 
reported, it seems likely that expression of tissue-
specific isoforms additionally contribute to functional 
diversity (Huiting et al. 2016, Wan et al. 2016). Differ-
ent roles of Gal-9 isoforms in Lovo cells and endothe-
lial cells have been demonstrated (Aanhane et al. 2018, 
Zhang et al. 2009). While Gal-9N and Gal-9M stimu-
late tube formation, Gal-9C inhibits sprouting. How-
ever, it remains to be elucidated whether this also ap-
plies for Gal-12 variants. 
 Our study also provided insights into the sub-
cellular localization of Gal-12 in colorectal cancer 
cells. Based on immunofluorescence and density gradi-
ent centrifugation analysis we demonstrate that Gal-12 
resides in and shuttles between the nucleus and cyto-
plasm of colorectal cancer cells. This finding in colo-
rectal cancer cells compares very well with studies of 
other cell types including sebocytes and adipocytes 
(Harrison et al. 2007). In adipocytes Gal-12 was addi-
tionally detected in the mitochondrial fraction and lo-
calized to lipid droplets (Hotta et al. 2001, Yang et al. 
2011). Since we did not extract the mitochondrial frac-
tion from the cytosol we cannot exclude the presence 
of Gal-12 in mitochondria of CRC cells. However, 
compared to the other studies, our data reveal for the 
first time nucleocytoplasmic shuttling of Gal-12 in a 
cell cycle dependent manner. Shuttling between both 
subcellular compartments has been only demonstrated 
for Gal-3 promoting its antiapoptotic activity and drug 
resistance (Arnoys et al. 2015, Takenaka et al. 2004, 
Yu et al. 2002). Several members of the galectin fam-
ily have been detected in the nucleus including Gal-1, -
2, -3 and -7 (Dvoránková et al. 2008, Kodet et al. 
2011). Although the precise nuclear transport pathway 
is still unknown distinct mechanisms have been pro-
posed including passive diffusion and active transport 
(Funasaka et al. 2014, Nakahara et al. 2006). For in-
stance, an importin-α/β-mediated nuclear localization 
signal and an exportin-1-mediated nuclear export have 
been confirmed for Gal-3 (Davidson et al. 2006, Naka-
hara et al. 2006, Nakahara & Raz 2007). In addition, 
posttranslational modifications have been shown to 
influence the subcellular distribution of galectins. 
While non-phosphorylated Gal-3 is exclusively found 
in the nucleus phosphorylation on Ser6 drives its nu-
clear export resulting in accumulation in the cytoplasm 
(Takenaka et al. 2004). The polypeptide sequence of 
Gal-12 contains several potential phosphorylation 
sites. It thus seems warranted to investigate in more 
detail whether phosphorylation acts as a switch in the 
subcellular distribution of Gal-12. Galectins are syn-
thesized on cytosolic ribosomes lacking a classical sig-
nal sequence usually characteristic for secreted pro-
teins (Leffler et al. 2002). Strikingly, they are secreted 
by a non-classical pathway acting on the cell surface or 
extracellular milieu thereby contributing to different 
processes such as cell-cell adhesion and adhesion of 
tumor cells to the vascular endothelium (Hughes 1999, 
Ilmer et al. 2016, Mori et al. 2015, Nobumoto et al. 
2008, Seelenmeyer et al. 2005). Compared to other 
members of the galectin family, secretion of Gal-12 
has not been demonstrated yet. Since it was predomi-
nantly localized in the nucleus and cytosol of the 
model cell line it seems likely that it mainly executes 
intracellular functions. However, changes in the intra- 
and extracellular distribution of other galectins have 
been linked to tumor growth and progression (Califice 
et al. 2004, Ilmer et al. 2016, Straube et al. 2011). Due 
to the spatial distribution of Gal-12 observed in the 
present study the question arises, whether intra- and 
extracellular distribution is affected upon disease pro-
gression and if this correlates with clinical features 
such as differentiation. In this context, identification of 
compartment-specific Gal-12 interacting proteins 
should represent a promising approach to understand 
how such interactions determine the biology of normal 
colon epithelium and how specific interference might 
contribute to colorectal tumorigenesis. 
 One of the most striking findings of this study 
was the observed dotted pattern of Gal-12 in the nu-
cleus that spared the nucleoli and was quite reminis-
cent of that of nuclear speckles. Nuclear speckles, also 
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known as SC-35 enriched splicing speckles, appear as 
20-50 irregular shaped dots in the nucleoplasm and are 
storage and assembly sites for the splicing machinery 
in the nucleus (Shpargel & Matera 2005). Alternative 
splicing contributes to the complexity of gene expres-
sion and plays an important role in processes such as 
cellular homeostasis and differentiation. Changes in 
this defined process can lead to interruption of protein-
protein interactions and expression of distinct and 
novel protein isoforms driving pathogenic conditions 
such as cancer (Yamaguchi et al. 1996). The splicing 
machinery is build up in a sequential manner by re-
cruitment of several small nuclear ribonucleoproteins 
(snRNPs) as well as splicing factors such as SC-35 to 
pre-mRNA (Wahl et al. 2009). SC-35 is required for 
the first step of the splicing reaction by mediating the 
interaction between the 5´and 3´splice site (Fu & Ma-
niatis 1992). Performing double immunofluorescence 
staining we demonstrate for the first time colocaliza-
tion of Gal-12 with SC35 positive nuclear speckles 
suggesting involvement in pre-mRNA splicing and 
processing. Colocalization of Gal-1 and -3 with nu-
clear speckles has been demonstrated in HeLa cells 
(Dagher et al. 1995, Vyakarnam et al. 1997). Both 
galectins are known to act as important pre-mRNA 
splicing factors and depletion from nuclear extracts 
reduces splicing activity (Dagher et al. 1995, Vyakar-
nam et al. 1997). Immunoprecipitation analysis has 
further confirmed binding of Gal-3 to Gemin-4 and 
heterogenous nuclear ribonucleoproteins (hnRNPs), 
which are involved in snRNP and spliceosome assem-
bly (Fritsch et al. 2016, Park et al. 2001, Sphargel & 
Matera 2005). Hence, modulating alternative splicing 
may be a common and important role of galectins con-
tributing to functional diversity of the cellular pro-
teome.  
 Although not demonstrated experimentally in 
the present study, it is tempting to speculate, that Gal-
12 might represent a novel pre-mRNA splicing regula-
tor. Galectins preferentially bind to N-
acetyllactosamine extensions in N- and O-glycans via 
the conserved CRD. Although glycosylated proteins 
are mainly detectable in the cytosol and extracellular 
milieu, glycosylated proteins have been also identified 
in the nucleus including nucleoporins, transcription 
factors and hnRNPs (Hanover et al. 1987, Ferraro et 
al. 1991). Addition of saccharides to nuclear extracts 
of HeLa cells abolished splicing activity of Gal-1 and -
3 suggesting carbohydrate dependent interaction 
(Dagher et al. 1995). Therefore, binding of Gal-12 to 
proteins of the spliceosome via the conserved CRD 
seems likely. However, it cannot be excluded that in-
tracellular functions of galectins, although saccharide-
inhibitable, are based on protein-protein interactions. It 
is possible that saccharide binding to the CRD induces 
a conformational change that disrupts the interaction of 
the galectin with other proteins. Intriguingly, similar to 
the observed subcellular distribution pattern of Gal-12, 
SR splicing factors undergo nuclearcytoplasmic shut-
tling in a cell-cycle dependent manner as well (Tripathi 
& Parnaik 2008). Translocation of SR proteins into the 
cytoplasm has been linked to RNA export where they 
stimulate translation (Huang et al. 2003). Binding of 
Gal-3 to mRNA especially during mitosis has been 
confirmed in the literature thereby contributing to en-
hanced half-life time of MUC4 mRNA known to be 
involved in proliferation (Coppin et al. 2017). Though 
direct interaction of Gal-12 with SR-proteins has not 
been demonstrated yet, it is reasonable to assume that 
this interaction may regulate its subcellular transport. 
 Galectins have attracted attention as potential 
modulators of tumor development and progression 
(Liu & Rabinovich 2005). Though little is known 
about the contribution of Gal-12 to tumorigenesis, our 
data provide the first evidence for the involvement of 
Gal-12 in alternative splicing and pre-mRNA process-
ing, suggesting it as a potent modulator of cellular ho-
meostasis of cells with a higher differentiation degree. 
Thus, our model cell line provides the basis for deci-
phering the biological consequence of re-expression of 
Gal-12 on CRC carcinogenesis at a molecular level in 
the future for the first time. In particular, identification 
of the galectin`s binding partners by Flag-tag mediated 
co-immunoprecipitation is now enabled.  
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